Company news
Gb Sciences, Inc. (OTC:GBLX) news
Gb Sciences, Inc. news releases on 6ix. Latest, Jun 11, 2019: GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis…
Press releases — page 2
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
June 11, 2019
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
May 28, 2019
GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
May 14, 2019
GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
April 16, 2019
Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
April 2, 2019
GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
March 28, 2019
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
March 26, 2019
Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
March 22, 2019
GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
March 19, 2019
GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
March 12, 2019
GB Sciences Completes Harvest of First Cannabis Crop in Partnership with The Louisiana State University Agricultural Research Center
January 16, 2019
GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium
December 14, 2018
GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars
December 12, 2018
Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit
December 11, 2018
GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
December 7, 2018
GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases
December 7, 2018
GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor
November 27, 2018
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
November 20, 2018
More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD
November 14, 2018
GB Sciences Expands into the Oklahoma Medical Cannabis Market
November 14, 2018
Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD
November 6, 2018
GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium
November 1, 2018
GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis
October 25, 2018
GB Sciences Harvests the First Hemp Crop in Colorado
October 16, 2018
GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles
October 10, 2018
GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018
October 9, 2018
GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds
October 3, 2018
GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization
October 2, 2018
Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
September 26, 2018
GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals
September 25, 2018
GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"
September 20, 2018
GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary
September 18, 2018
The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
August 23, 2018
GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop
August 21, 2018
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
August 15, 2018
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
August 6, 2018
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
August 2, 2018
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
July 31, 2018
GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
July 16, 2018
GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
July 9, 2018
GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain
June 27, 2018
GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
June 25, 2018
GB Sciences Puts Its Grey Matter To Work Solving The Big Green Riddle...
May 23, 2018
GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Covered By Medical Cannabis Legislation
May 22, 2018
GB Sciences' Acquisition Of NevadaPURE Is Terminated
May 9, 2018
Marijuana Stocks for Investors in the Free Cannabis Investor Magazine
May 6, 2018
GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
April 19, 2018
Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients
April 17, 2018
GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel
April 12, 2018
GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
April 10, 2018